Abstract
Astragalus membranaceus (Huang Qi, HQ) is a staple in Traditional Chinese Medicine, often used to support colon cancer treatment. However, the specific molecular pathways it influences have remained unclear. This study employs an integrated approach—combining network pharmacology, experimental validation, and molecular docking—to investigate the anti-cancer effects of HQ and its primary isoflavonoids, formononetin (FMNT) and calycosin (CS). The findings reveal that these compounds significantly inhibit colon cancer cell proliferation and migration by targeting the ERK1/2 and PI3K-Akt signaling pathways, suggesting their potential as therapeutic supplements.
Introduction
Colon cancer is a leading cause of cancer-related mortality worldwide, characterized by poor prognosis and high recurrence. While HQ is clinically recognized for its therapeutic potential, identifying its active ingredients and their precise biological targets is essential for scientific validation. This research focuses on FMNT and CS to decode the "black box" of HQ's mechanism of action against colon malignancies, moving beyond traditional observation into high-resolution molecular mapping.
Methodology
The study utilized a three-tiered integrated approach:
- Network Pharmacology: Databases like TCMSP and GeneCards were mined to identify 147 overlapping targets between HQ's bioactive compounds and colon cancer. Protein-protein interaction (PPI) networks were constructed to identify hub genes.
- Experimental Validation: The effects of HQ extract, FMNT, and CS were tested on HT-29 and Caco2 human colon cancer cell lines. Assays included MTT and EdU for growth, flow cytometry for apoptosis, and Western blotting for protein expression (specifically p-ERK1/2 and p-Akt).
- Molecular Docking: Computational simulations predicted the physical binding affinity between FMNT/CS and key signaling proteins in the MAPK/ERK pathway, such as EGFR, BRAF, and MEK.
Results and Discussion
Network analysis identified 147 common targets, including major players like AKT1, TP53, and EGFR. Enrichment analysis highlighted the MAPK (ERK1/2) and PI3K-Akt pathways as the primary regulatory targets for FMNT and CS.
Experimental results showed that HQ, FMNT, and CS inhibited cell viability in a dose-dependent manner and significantly induced programmed cell death. Notably, the treatments suppressed the Epithelial-Mesenchymal Transition (EMT)—a key process in metastasis—by increasing E-cadherin and decreasing Vimentin expression, effectively "locking" cancer cells in place and reducing their migratory capacity.
Western blot analysis confirmed a striking reduction in phosphorylated ERK1/2 (the active form) levels without changing total protein amounts. Molecular docking further supported these findings, showing high binding affinities (lower than -7 kcal/mol) between the compounds and MAPK pathway kinases, suggesting they act as natural inhibitors of these growth-promoting enzymes.
Conclusion
This study demonstrates that Astragalus membranaceus and its components FMNT and CS exert potent anti-colon cancer effects by primarily inhibiting the ERK1/2 signaling pathway. While these in vitro and computational results are promising, the authors acknowledge the need for future in vivo studies to evaluate systemic efficacy and potential synergy with standard chemotherapies like 5-Fluorouracil. These findings provide a robust scientific basis for using HQ as a therapeutic supplement to enhance chemotherapeutic outcomes for colon cancer patients.
Summary updated